Open AccessResponse to pazopanib‐based combination regimen in a case of FGFR3 amplified gastric adenocarcinoma
Author(s) -
Limaye Sewanti,
Patil Darshana,
Akolkar Dadasaheb,
Srivastava Navin,
Patil Revati,
Apurwa Sachin,
Patil Sanket,
John Jinumary,
Gosavi Rahul,
Nesargikar Prabhu,
Kumar Prashant,
Datta Vineet,
Bose Chirantan,
Raazi Zarrine,
Srinivasan Ajay,
Datar Rajan
Publication year - 2021
Publication title -
clinical case reports
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.21
H-Index - 9
ISSN - 2050-0904
DOI - 10.1002/ccr3.4986
Subject(s) - medicine , pazopanib , angiogenesis , gastric adenocarcinoma , regimen , cancer , adenocarcinoma , angiogenesis inhibitor , oncology , cancer research , pharmacology , sunitinib
Angiogenesis inhibitors (AGI) are not presently used for the treatment of gastric cancers. This report demonstrates that angiogenesis inhibitor can be safely and effectively used in combination with cytotoxic anti‐cancer agents for treatment of Gastric cancers.